CSPC Pharmaceutical Group (1093) Earnings: 9M Net Income Hits 3.51 Billion Yuan with Revenue of 19.89 Billion Yuan

CSPC Pharmaceutical Group on Smartkarma

Analysts on Smartkarma, like Tina Banerjee, are closely monitoring CSPC Pharmaceutical Group (1093 HK) as the company navigates challenges in its revenue stream. In one report titled “CSPC Pharma (1093 HK): Finished Drugs Drag 1H25; 2H25 Expected To End with More Licensing Deals,” the focus is on the 18.5% YoY revenue drop in 1H25 due to lower finished drug sales. Despite this setback, optimism surrounds future revenue prospects with anticipated collaborations and entry into the high-end market for competitive pricing.

Similarly, in another analysis, “CSPC Pharmaceutical (1093 HK): Finished Drugs Drag 1Q25; Out Licensing And New Launches To Be Key,” the emphasis lies on a 22% YoY revenue decline in 1Q25 with stable operating margins. The report highlights the importance of out-licensing and new product launches in driving future revenue growth. Analysts note the significance of license and collaboration agreements for the company’s upcoming products in ensuring future revenue visibility and stability.

A look at CSPC Pharmaceutical Group Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

According to Smartkarma Smart Scores, CSPC Pharmaceutical Group is projected to have a positive long-term outlook. With high scores in Dividend and Value, the company is seen as financially stable and potentially offering good returns to investors. Additionally, its strong scores in Resilience and Momentum indicate a solid ability to weather market fluctuations and maintain steady growth over time. Though the Growth score is not as high, CSPC Pharmaceutical Group‘s focus on manufacturing and selling pharmaceutical products, including innovative drugs and antibiotics, positions it well for future expansion and success.

CSPC Pharmaceutical Group Limited, a company specializing in the manufacturing and sale of pharmaceutical products such as vitamin C, antibiotics, and generic drugs, boasts an overall positive outlook based on Smartkarma Smart Scores. With a strong emphasis on innovation in drug development, the company is poised to capitalize on emerging trends in the pharmaceutical industry. Investors may find CSPC Pharmaceutical Group an attractive prospect given its solid performance across various key factors, signaling a promising trajectory for the company’s future growth and stability.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma